Pfizer, looking to expand RSV vaccine's reach, touts its benefits in immunocompromised adults

Locked in a closely watched respiratory syncytial virus (RSV) vaccine competition, Pfizer aims to expand the reach of its offering Abrysvo.

Monday, Pfizer said Abrysvo elicited a strong response in adults of various ages with compromised immune systems.